Royalty Report: Drugs, Cancer, Disease – Collection: 248292


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Disease
  • Therapeutic
  • Medical

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 248292

License Grant
This amendment changes the Licensee to Licensee or its Affiliate, compensation and other details.  The agreement includes patents relating to Tryptophan.
License Property
As of the March 28, 2006 the patents include
–  Regulation of T-Cell Mediated Immunity by Tryptophan
–  High Affinity Tryptophan Transporter
–  Antigen-Presenting Cell Populations and Their Use as Reagents for Enhancing of Reducing Immune Tolerance
–  Chemokine Receptor Antagonists as Therapeutic Agents
–  Regulation of T Cell-Mediated Immunity by D Isomers of Inhibitors of Indoleamine-2,3-Dioxygenase
–  Inhibitors of Indoleamine-2,3-Dioxygenase and Methods of Use
–  Regulation of T Cell-Mediated Immunity by D Isomers of Inhibitors of Indoleamine-2,3-Dioxygenase, and,
–  Use of Inhibitors of lndoleamine-2,3-Dioxygenase in Combination with Other Therapeutic Modalities
Field of Use
Licensee was formed for the purpose of developing treatments for cancer and other diseases.

IPSCIO Record ID: 248355

License Grant
The University grants an exclusive right and license under the Licensed Patents and Licensed Technology to make, use, import, offer to sell and sell Licensed Products for the Field of Use in the Licensed Territory during the term of this Agreement.
License Property
The patents are for Regulation of T-Cell Mediated Immunity by Tryptophan;  High Affinity Try to ban Transporter;  Antigen-Presenting Cell Populations and Their Use as Reagents for Enhancing or Reducing Immune Tolerance;  Chemokine Receptor Antagonists as Therapeutic Agents; and,  Regulation of T Cell-Mediated Immunity by D Isomers of Inhibitors of Indoleamioe-2,3 -Dioxygenase.
Field of Use
The Field of Use means any and all medical applications, including without limitation, prevention, diagnostics, and therapy, including action as an adjuvant.

IPSCIO Record ID: 226529

License Grant
The parties agreed to collaboratively develop sitravatinib in Asia (excluding Japan and certain other countries), Australia and New Zealand (the Licensed Territory). Under this Agreement, Licensor granted Licensee an exclusive license to develop, manufacture and commercialize sitravatinib in the Licensed Territory, with Licensor retaining exclusive rights for the development, manufacturing and commercialization of sitravatinib outside the Licensed Territory.
License Property
Sitravatinib is an oral, spectrum-selective kinase inhibitor that potently inhibits specific receptor tyrosine kinases (“RTKs”). RTKs are families of kinases involved in the transmission of signals that regulate cell growth, survival, and migration and include TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET. Sitravatinib addresses cancer via two distinct mechanisms: directly, by targeting RTKs that drive tumor growth through mutation, and indirectly, by modulating immune regulatory cells to stimulate the body’s immune response to tumors. Sitravatinib’s potent inhibition of TAM and split family receptors may help overcome resistance to immune checkpoint inhibitors and stimulate the body’s immune response to help detect and destroy tumor cells. Blocking the signaling of these RTKs enhances the ability of T-cells (a type of white blood cell that is of key importance to the immune system) to recognize and eliminate tumor cells and modifies the tumor immune environment to enable a more productive immune response. The ability of sitravatinib to enhance the activity of immune checkpoint inhibitors was demonstrated in nonclinical cancer models.
Field of Use
This agreement pertains to the drug industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.